Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Global stocks mostly rose Thursday on easing trade tensions, with London and Frankfurt hitting record highs ahead of key US employment data.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

She has a postgraduate degree in International Journalism from City, University of London. Drugmaker Pfizer ... loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...